Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Beta Drugs Limited, is an unlisted public company incorporated on 21 September, 2005. It is classified as a public limited company and is located in Baddi, Himachal Pradesh. It's authorized share capital is INR 10.00 cr and the total paid-up capital is INR 9.61 cr.
Beta Drugs Limited's operating revenue range is INR 100 cr - 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has increased by 23.88% over the previous year. At the same time, it's book networth has increased by 24.26%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
25.18%
7.46%
16.58%
20.52%
-2.92%
27.17%
-4.06
-2.8
-0.84
-0.64
-0.22
-0.01
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(2)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
HDFC Bank Limited
No. of Loans: 4
Total Amount : 15.1 cr
UCO Bank
No. of Loans: 1
Total Amount : 7.5 cr
Small Industries Development Bank of India
No. of Loans: 3
Total Amount : 4.5 cr
BMW India Financial Services Private Limited
No. of Loans: 1
Total Amount : 1.1 cr
The Federal Bank Limited
No. of Loans: 3
Total Amount : 0.9 cr
Axis Bank Limited
No. of Loans: 1
Total Amount : 0.7 cr
Tata Motors Finance Limited
No. of Loans: 1
Total Amount : 0.2 cr
Bank of Baroda
No. of Loans: 3
Total Amount : 0.1 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Balwant Singh
Shareholder
|
01089968 | 10 years |
| Managing Director | Varun Batra
Shareholder
|
02148383 | 10 years |
| Managing Director | Rahul Batra
Shareholder
|
02229234 | 10 years |
| CFO | Nipun Arora | <HIDDEN> | 4 years |
| Director | Manmohan Khanna | 07888319 | 7 years |
| Director | Rohit Parti | 07889944 | 7 years |
| Whole-time Director | Seema Chopra | 08510586 | 5 years |
| Whole-time Director | Ashutosh Shukla | 09461568 | 3 years |
| CS | Rajni Brar | <HIDDEN> | 7 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| ADLEY LIFESCIENCES PRIVATE LIMITED |
Strike Off
|
1.0 L | 2 | Haryana |
| BT ASSOCIATES PRIVATE LIMITED |
Active
|
1.0 L | 2 | Haryana |
| ADLEY RESORTS PRIVATE LIMITED |
Strike Off
|
1.0 L | 2 | Chandigarh |
| BETA RESEARCH PRIVATE LIMITED |
Not available for efiling
|
1.0 L | 2 | Haryana |
| ADLEY LAB LIMITED |
Active
|
1.8 Cr | 2 | Punjab |
| ADLEY FORMULATIONS PRIVATE LIMITED |
Active
|
1.3 Cr | 3 | Haryana |
| KEDGE PHARMACIA (INDIA) PRIVATE LIMITED |
Strike Off
|
2.4 L | 1 | Haryana |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| ADLEY FORMULATIONS PRIVATE LIMITED | Haryana | 2018 | ₹ 1.3 Cr |
| ADLEY LAB LIMITED | Punjab | 1992 | ₹ 1.8 Cr |
| BETA RESEARCH PRIVATE LIMITED | Haryana | 2022 | ₹ 1.0 L |
The incorporation date of BETA DRUGS LIMITED is 21 September, 2005
The authorized share capital of BETA DRUGS LIMITED is INR ₹ 10.0 Cr.
The paid-up capital of BETA DRUGS LIMITED is INR ₹ 9.6 Cr.
The registered address of BETA DRUGS LIMITED is Village Nandpur Baddi Himachal Pradesh - 174101
The CIN number of BETA DRUGS LIMITED is L24230HP2005PLC028969.
Expand
Delete
Collapse
See
details
